Efficient Single Nucleotide Editing with CRISPR
News Mar 01, 2017 | Original story from The Institute of Basic Research
Cystic fibrosis, sickle cell anemia, Huntington's disease and phenylketonuria are all examples of disorders caused by the mutation of a single nucleotide, a building block of DNA. The human DNA consists of approximately 3 billion nucleotides of four types: Adenine (A), cytosine (C), guanine (G), and thymine (T). In some cases, the difference of just one nucleotide can bring serious consequences. Scientists hope to cure these diseases by substituting the incorrect nucleotide with the correct one. However, it is technically challenging to replace a single nucleotide with the current gene editing tool, CRISPR-Cas9. Scientists at the Center for Genome Engineering, within the Institute for Basic Science (IBS) have used a variation of the popular gene editing technique CRISPR-Cas9 to produce mice with a single nucleotide difference. Their findings are published in Nature Biotechnology.
The most recent and highly successful CRISPR-Cas9 technique works by cutting around the faulty nucleotide in both strands of the DNA and cuts out a small part of DNA. Conversely, IBS biologists used a variation of the Cas9 protein (nickase Cas9, nCas9) fused with a protein called cytidine deaminase, a.k.a. Base Editor, which is able to substitute one nucleotide into another. In this way, no DNA deletion occurs, but just one nucleotide substitution. These types of deaminases have been developed and tested in cultured cell lines by David Liu's group at Harvard and Keiji Nishda and his colleagues at Kobe University in 2016. The IBS team advanced the technique further by applying it to mouse embryos.
The scientists tested the CRISPR-nCas9-cytidine deaminase fusion in mice by changing a single nucleotide in the dystrophin gene (Dmd) or the tyrosinase gene (Tyr). They were successful in both cases: Embryos with the single nucleotide mutation in the Dmd gene led to mice producing no dystrophin protein in their muscles, and mice with the Tyr mutation showed albino traits. Dystrophin is indeed connected with the muscular dystrophin disease and tyrosinase controls the production of melanine.
Moreover, these single-nucleotide substitutions appeared only in the target position. This is important because it means that only the correct nucleotide is substituted. "We showed here for the first time that programmable deaminases efficiently induced base substitutions in animal embryos, producing mutant mice with disease phenotypes. This is a proof-of-principle experiment. The next goal is to correct a genetic defect in animals. Ultimately, this technique may allow gene correction in human embryos," expressed KIM Jin-Soo, Director of the Center and leading author of this study.
Neurochoice Big Idea Initiative to Fight Opioid Epidemic in USANews
Neurochoice brings together neuroscientists, psychologists, public policy scholars and others to tackle drug addiction and find better treatments and policies for dealing with the problem.READ MORE
FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer TherapiesNews
Oncomine Dx Target Test returns results in days, helping physicians rapidly develop treatment plans for the most common form of lung cancer.
HIV Envelope Trimer Immunization Approach OptimizedNews
Optimized immunizations reliably elicit protective antibodies in preclinical study, marking an important milestone on the way to an effective HIV vaccine.READ MORE
Comments | 0 ADD COMMENT
Outsourcing in Clinical Trials Southern California
Sep 27 - Sep 28, 2017